Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health - Episode 6

Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

, , ,

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

EP. 1: Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners
EP. 2: The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages
EP. 3: The Crucial Impact of Early Intervention in Preventing T1D Stage Progression
EP. 4: Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening
EP. 5: Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities
Now Viewing
EP. 6: Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact
EP. 7: Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights
EP. 8: Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement
EP. 9: Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management